Today: Today: Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sold 18,479 Shares

Today: Ligand Pharmaceuticals Inc. (LGND) Director Jason Aryeh Sold 18,479 Shares

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director Jason Aryeh sold 18,479 shares of the stock in a transaction on Friday, November 25th. The shares were sold at an average price of $107.31, for a total value of $1,982,981.49. Following the sale, the director now directly owns 58,959 shares in the company, valued at approximately $6,326,890.29. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jason Aryeh also recently made the following trade(s): On Friday, November 18th, Jason Aryeh sold 6,330 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $105.28, for a total value of $666,422.40.

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) opened at 106.77 on Monday. Ligand Pharmaceuticals Inc. has a 1-year low of $82.06 and a 1-year high of $139.79. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of 305.93 and a beta of 1.43. The firm’s 50 day moving average price is $98.82 and its 200-day moving average price is $112.37.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.03. The firm earned $21.62 million during the quarter, compared to analysts’ expectations of $23.64 million. Ligand Pharmaceuticals had a net margin of 8.51% and a return on equity of 9.98%. The firm’s revenue for the quarter was up 22.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.57 earnings per share. On average, equities analysts anticipate that Ligand Pharmaceuticals Inc. will post $3.40 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors boosted its position in shares of Ligand Pharmaceuticals by 8.1% in the third quarter. BlackRock Fund Advisors now owns 1,584,794 shares of the biotechnology company’s stock worth $161,744,000 after buying an additional 118,327 shares during the period. Vanguard Group Inc. boosted its position in shares of Ligand Pharmaceuticals by 8.0% in the second quarter. Vanguard Group Inc. now owns 1,515,814 shares of the biotechnology company’s stock worth $180,790,000 after buying an additional 111,807 shares during the period. William Blair Investment Management LLC boosted its position in shares of Ligand Pharmaceuticals by 2.1% in the second quarter. William Blair Investment Management LLC now owns 1,255,277 shares of the biotechnology company’s stock worth $149,717,000 after buying an additional 25,825 shares during the period. FMR LLC boosted its position in shares of Ligand Pharmaceuticals by 8.2% in the second quarter. FMR LLC now owns 1,055,463 shares of the biotechnology company’s stock worth $125,885,000 after buying an additional 80,200 shares during the period. Finally, Victory Capital Management Inc. boosted its position in shares of Ligand Pharmaceuticals by 168,987.6% in the third quarter. Victory Capital Management Inc. now owns 940,127 shares of the biotechnology company’s stock worth $95,949,000 after buying an additional 939,571 shares during the period.

Several brokerages have recently commented on LGND. CJS Securities decreased their price objective on Ligand Pharmaceuticals from $130.00 to $125.00 and set an “outperform” rating for the company in a report on Wednesday, September 28th. Roth Capital set a $154.00 price objective on Ligand Pharmaceuticals and gave the company a “buy” rating in a report on Monday, November 21st. TheStreet lowered Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 7th. Craig Hallum increased their price objective on Ligand Pharmaceuticals from $150.00 to $160.00 in a report on Wednesday, October 5th. Finally, Zacks Investment Research upgraded Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 9th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $139.70.

Ligand Pharmaceuticals Company Profile

Related posts

Leave a Comment